FORTRESS BIOTECH, INC. (NASDAQ:FBIO) Files An 8-K Financial Statements and Exhibits
Item9.01 of the Original 8-K to include the financial information
required under Item9.01, which was not previously filed with the
Original 8-K. Except as stated in this Explanatory Note, no other
information contained in the Original 8-K is changed.
Item9.01 Financial Statements and Exhibits.
(a) Financial Statements of Businesses Acquired
The financial statements for NHLD required under Item9.01(a) of
Form 8-K are attached hereto as Exhibits 99.1, 99.2, 99.3 and
99.4 to this Amendment No.1 and are incorporated herein by
reference.
(b) Pro Forma Financial Information
The pro forma financial information required under Item9.01(b) of
Form 8-K is attached hereto as Exhibit 99.5 to this Amendment
No.1 and is incorporated herein by reference.
(d) Exhibits.
| ExhibitNo. | Description | |
|
2.1 |
Agreement and Plan of Merger by and among Fortress Biotech, Inc., FBIO Acquisition, Inc. and National Holdings Corporation, dated April 27, 2016 (incorporated by reference to Exhibit 2.1 to the Companys Current Report on Form 8-K filed on April 28, 2016) |
|
|
2.2 |
Amendment No. 1 to Agreement and Plan of Merger by and among Fortress Biotech, Inc., FBIO Acquisition, Inc., and National Holdings Corporation, dated August 12, 2016 (incorporated by reference to Exhibit 2.1 to the Companys Current Report on Form 8-K filed on August 12, 2016) |
|
|
23.1 |
Consent of EisnerAmper LLP | |
|
99.1 |
Audited Consolidated Financial Statements of National Holdings Corporation for the years ended September 30, 2015 and September 30, 2014 (incorporated by reference to NHLDs Annual Report on Form 10-K filed on December 28, 2015) |
|
99.2 |
Unaudited Condensed Consolidated Financial Statements of National Holdings Corporation as of December31, 2015 for the three months ended December31, 2015 (incorporated by reference to NHLDs Quarterly Report on Form 10-Q filed on February16, 2016) |
|
|
99.3 |
Unaudited Condensed Consolidated Financial Statements of National Holdings Corporation as of March 31, 2016 for the six months ended March 31, 2016 (incorporated by reference to NHLDs Quarterly Report on Form 10-Q filed on May 16, 2016) |
|
|
99.4 |
Unaudited Condensed Consolidated Financial Statements of National Holdings Corporation as of June 30, 2016 for the nine months ended June 30, 2016 (incorporated by reference to NHLDs Quarterly Report on Form 10-Q filed on August 15, 2016) |
|
|
99.5 |
Unaudited Pro Forma Condensed Combined Statement of Operations for the six months ended June30, 2016 and the year ended December31, 2015 |
About FORTRESS BIOTECH, INC. (NASDAQ:FBIO)
Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company’s product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109. FORTRESS BIOTECH, INC. (NASDAQ:FBIO) Recent Trading Information
FORTRESS BIOTECH, INC. (NASDAQ:FBIO) closed its last trading session down -0.01 at 2.62 with 51,796 shares trading hands.
